<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immune neutropenia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immune neutropenia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immune neutropenia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas D Coates, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neutropenia is defined as an absolute neutrophil count (ANC) of less than 1500/microL. The ANC is equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:</p><p>ANC = WBC (cells/microL) x percent (PMNs + bands) ÷ 100</p><p>Neutrophilic metamyelocytes and younger forms are not included in this calculation (<a class="calc calc_professional" href="/d/html/13483.html" rel="external">calculator 1</a>).</p><p>Most cases of neutropenia are acquired and are due to apoptosis of myeloid cells or increased destruction [<a href="#rid1">1</a>], usually resulting from immunologic mechanisms, which can be antibody or cytotoxic-T cell related [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Causes of neutropenia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>If the cause of the neutropenia is decreased production of granulocytes, the risk of infection begins to increase at an ANC below 500/microL (<a class="graphic graphic_table graphicRef63903" href="/d/graphic/63903.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, however, the risk of infection is related to the adequacy of the marrow reserve pool. Patients with normal marrow granulocyte production may have a very low ANC and be at no increased risk of infection because of the neutropenia [<a href="#rid3">3-5</a>].</p><p></p><p>This topic will review the immune neutropenias. Other causes of acquired neutropenia, such as drugs and infections, are discussed separately. (See  <a class="medical medical_review" href="/d/html/8374.html" rel="external">"Drug-induced neutropenia and agranulocytosis"</a> and  <a class="medical medical_review" href="/d/html/8372.html" rel="external">"Infectious causes of neutropenia"</a>.)</p><p class="headingAnchor" id="H5127336"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Immune destruction of mature/maturing neutrophils accounts for many cases of isolated neutropenia, but most affected individuals have normal marrow reserves and little or no increased propensity to infection, regardless of the degree of neutropenia. </p><p>In addition to immune mechanisms, some individuals with isolated neutropenia have a normal variant in which mild neutropenia (eg, usually &gt;1000/microL) is associated with the Duffy null [Fy(a-b-)] red blood cell phenotype. This condition is more common in individuals of African descent and in Sephardic Jews, West Indians, Yemenites, Greeks, and Arabs; it was formerly called constitutional neutropenia or benign ethnic neutropenia and is described separately. (See  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Normal variants &lt;1500/microL'</a>.) </p><p>The true incidence of immune neutropenia is unknown; some reports estimate a prevalence of 1:100,000 in children younger than 10 years, with a slight female predominance [<a href="#rid6">6</a>]. However, the incidence has been reported to be as high as 1:6300 [<a href="#rid7">7,8</a>].</p><p>There is confusing overlap between the immune neutropenia syndromes of chronic benign neutropenia of infancy, chronic benign neutropenia (CBN), autoimmune immune neutropenia (AIN), and chronic idiopathic neutropenia (CIN). In fact, they are very similar and differ only in a few features related to the age of presentation and duration of neutropenia. The vast majority of patients have normal bone marrow reserve and little if any increased propensity to infection regardless of the degree of neutropenia. Isoimmune neonatal neutropenia and neutropenia associated with immunodeficiency are similar as well. They differ mainly in that the source of the antibody is known. The fact that assays for antineutrophil antibodies have a significant false negative rate and in fact are not routinely available [<a href="#rid9">9,10</a>] probably explains the existence of CIN, which is essentially identical to AIN except that antibody tests are negative. To add to the confusion, a small subset of each of these groups has been reported to have serious infections and have even been treated with granulocyte colony-stimulating factor (G-CSF). Careful review of some of the reports fails to uncover evidence that the illness was caused by the neutropenia, and in some reports, patients with severe forms of congenital neutropenia were included in articles about CBN. </p><p>Inherited disorders of immune regulatory genes that are associated with aberrant antibody production, cytotoxic lymphocyte activation, and inflammasomopathies are increasingly recognized [<a href="#rid10">10</a>]. Examples include dysregulated B- and T-lymphocyte functions with concomitant AIN in association with inherited gene variants of <em>TACI</em>, <em>BAFFR</em>, <em>ACKR1/DARC</em>, <em>LRBA</em>, <em>CTLA 4</em>. Cellular immune mechanisms may also play a prominent role in the development of immune neutropenia whether there are detectable autoantibodies, such as large granular lymphocyte syndromes of T- and NK-cell types or in chronic idiopathic neutropenia, especially in adults with clonal T-cell populations.</p><p>For these reasons, we feel it is more important to focus on factors that affect risk to the patient and may modify treatment (see  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Causes of neutropenia'</a>). The fundamental issues with any neutropenia are:</p><p class="bulletIndent1"><span class="glyph">●</span>Can the patient provide neutrophils to the site of infection?</p><p class="bulletIndent1"><span class="glyph">●</span>Does the presence of neutropenia indicate some other significant disease state that may put the patient at risk for infection?</p><p></p><p>If the marrow reserve is good, neutrophils can get to the site of infection [<a href="#rid4">4,5,11</a>]. Underlying autoimmune disorders, such as systemic lupus erythematosus or polyarteritis nodosum, can cause vasculitis with mouth sores and mucositis independent of neutropenia that can put the patient at significant risk for infection. If the immune neutropenia is an autoimmune manifestation of an underlying immunodeficiency state, the patient may be at risk for infection because of the immunodeficiency, rather than the neutropenia. </p><p>Importantly, some autoimmune disorders can cause severe depression of myeloid reserve and put the patient at great risk because of neutropenia as well as vasculitis. In general, there are four scenarios to consider with autoimmune neutropenia:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has antibody-mediated neutropenia with normal marrow reserve. The patient will generally be asymptomatic and at no increased risk of infection. This is the most common situation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has antibody-mediated neutropenia as an autoimmune manifestation of an underlying immunodeficiency state. The marrow reserve is likely normal. The patient may be at increased risk of infection, not because of the neutropenia but because of the underlying immunodeficiency. As primary immunodeficiency is not common, this is not a common situation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has antibody-mediated or cytotoxic T cell mediated neutropenia. The marrow reserve is normal. However, the patient is very symptomatic with gingivitis, painful mucosal ulcers, and other evidence of inflammation because of immune vasculitis. They may be at increased risk of infection because of the underlying disorder causing the mucosal symptoms. The neutropenia is a sign of the immune disorder but is likely not contributing to the symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has cytotoxic T cell or possibly antibody-mediated neutropenia. The myeloid precursors are markedly decreased in the marrow. The patient is at high risk of infection if the absolute neutrophil count (ANC) is very low. The patient is likely very symptomatic with gingivitis, painful mucosal ulcers, and other evidence of inflammation, and will be at significantly increased risk of serious infection because of the neutropenia and underlying autoimmune disorder. Such patients may have disruption of mucosal surfaces because of vasculitis, which, in combination with the decreased marrow production of granulocytes, puts them at significant risk for bacterial invasion.</p><p></p><p>Most cases of immune neutropenia fall into the first scenario. If the patient has significant symptoms suggesting mucosal invasion, frank sepsis, or unusual infection, they will likely require bone marrow aspiration to determine the degree of myeloid reserve and other evaluations to determine the nature of the underlying autoimmune disorder. Treatment is aimed at the underlying diagnosis. G-CSF may be indicated if the myeloid reserve is significantly decreased.</p><p>Neutropenia due to cytotoxic lymphocytes is seen in the so-called "lymphoproliferative disorders of large granular lymphocytes" (LDLGL). These patients are older and often have a rheumatoid arthritis-like clinical presentation and mild splenomegaly [<a href="#rid10">10,12</a>]. The myeloid reserve can be markedly reduced, and they are at significant risk of infection related to the neutropenia. This disorder is discussed separately (See  <a class="medical medical_review" href="/d/html/16360.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia"</a> and  <a class="medical medical_review" href="/d/html/4536.html" rel="external">"Treatment of large granular lymphocyte leukemia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DETECTION OF ANTINEUTROPHIL ANTIBODIES</span><span class="headingEndMark"> — </span>The presence or absence of detectable antibody in the serum is generally not helpful in the diagnosis and management of immune neutropenia, and management decisions are not based on the results of antineutrophil antibody testing [<a href="#rid9">9</a>]. Limited availability of testing and lack of standardization of assays limit the utility of such approaches.</p><p>Several tests are available for detecting antineutrophil antibodies, including agglutination, cytotoxicity, direct and indirect immunofluorescence, direct and indirect antiglobulin assays, and tests that use binding of staphylococcal protein A to immunoglobulins on the surface of cells [<a href="#rid9">9,13</a>]. Antineutrophil antibodies can be present in the absence of neutropenia (ie, false positive results) [<a href="#rid14">14</a>]. There is also a significant rate of false negative results, unless several different detection methods are used, yet few laboratories carry out all of the approaches. </p><p class="headingAnchor" id="H3"><span class="h1">NEONATAL ISOIMMUNE (ALLOIMMUNE) NEUTROPENIA</span><span class="headingEndMark"> — </span>Moderate to severe neutropenia can occur in newborn infants due to the transplacental passage of IgG antibodies to neutrophil-specific antigens inherited from the father [<a href="#rid7">7,15,16</a>]. Rarely, the antibody can arise from autoimmune neutropenia in the mother [<a href="#rid7">7,17,18</a>]. The pathogenesis of the former disorder is identical to that of Rh hemolytic disease, while the latter is identical to maternal immune thrombocytopenia (ITP). The incidence has been estimated at 2 per 1000 live births [<a href="#rid15">15</a>].</p><p>Infants with isoimmune neutropenia can present with sepsis or be asymptomatic. Since neutropenia is frequently induced by sepsis in infants [<a href="#rid19">19-22</a>], it may be difficult to determine whether the neutropenia resulted in sepsis or vice versa. Bone marrow examination shows normal cellularity with a late myeloid arrest, although antibody-mediated early arrests have been seen. Antinuclear antibody can be detected in infant and maternal serum and may show specificity for the father's neutrophils, rather than the mother's [<a href="#rid15">15</a>]. The decision to treat a severely neutropenic, possibly septic infant is never dependent on bone marrow findings or antibody tests. It is not unreasonable to treat with granulocyte colony-stimulating factor (G-CSF) and complete the evaluation once the patient has been stabilized. A decision to continue G-CSF does require establishing a diagnosis of severe congenital neutropenia. (See  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/6059.html" rel="external">"Management of children with non-chemotherapy-induced neutropenia and fever"</a> and  <a class="medical medical_review" href="/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p>This type of neutropenia is usually noted in an otherwise normal infant. Antibiotics are usually given, because of the possibility of neonatal sepsis. Most of these children typically do well, with no culture proof of infection. We usually observe the peripheral blood counts in this setting and do not proceed with marrow aspiration. The role of G-CSF is uncertain, although some patients have responded to treatment with this agent [<a href="#rid18">18,23,24</a>]. Little benefit of G-CSF was noted in a controlled trial of neonates with neutropenia and early-onset sepsis [<a href="#rid25">25</a>].</p><p>Recovery is usually uneventful, with no episodes of serious infection. The neutropenia resolves within 12 to 15 weeks, although prolonged neutropenia for 24 weeks has been seen.</p><p class="headingAnchor" id="H4"><span class="h1">AUTOIMMUNE NEUTROPENIA</span><span class="headingEndMark"> — </span>Autoimmune neutropenia (AIN) is caused by granulocyte-specific antibodies and has been associated with a variety of underlying diseases including infection (eg, hepatitis B), collagen vascular disease, primary abnormalities of B or T lymphocytes or natural killer (NK) cells (eg, autoimmune lymphoproliferative syndrome, ALPS), a deficiency of regulatory T cells, immune thrombocytopenia (ITP), and autoimmune hemolytic anemia [<a href="#rid26">26-29</a>].</p><p>In most cases, however, AIN is not associated with other illness or underlying disease and is referred to as <strong>chronic benign neutropenia</strong> (CBN/AIN) [<a href="#rid30">30,31</a>]. In pediatrics, this syndrome typically occurs in infants between the ages of 5 and 15 months but the range extends from one month to adulthood. In one registry series, the median age at onset was eight months, the median age of recovery was 25 months, and 90 percent recovered by five years of age, with the remainder recovering by 11 years [<a href="#rid8">8</a>]. Earlier age at diagnosis and absence of monocytosis were associated with earlier recovery. In contrast, secondary AIN is more common in adults, most often occurring between the ages of 40 and 60 [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Antineutrophil antibodies are detected in 98 to 100 percent of patients with AIN if several testing methods are used [<a href="#rid7">7,8</a>]. If only a single modality is used, the positive rate is lower [<a href="#rid30">30,31,33</a>]. The serum concentration can vary over time and may not be detectable if the patient is entering remission [<a href="#rid30">30</a>]. The antibodies are directed against a variety of neutrophil-specific antigens. In one large series, for example, most antibodies were directed against Fc gamma RIIIb or the adhesion molecule CD11b/CD18 (also called complement receptor type 3) [<a href="#rid30">30</a>]. In addition, 31 percent of autoantibodies showed preferential binding to PMN from NA1 homozygous donors; the NA1 antigen is located on Fc gamma RIIIb. The antibodies are usually IgG but are occasionally IgM.</p><p>Although an association between specific autoantibodies and HLA-DR or HLA-DQ alleles has been described [<a href="#rid34">34</a>], AIN is unlikely to be strictly a genetic disease [<a href="#rid30">30</a>]. Increased levels of soluble Fas ligand suggest an apoptotic mechanism in this disorder, as is the case with many neutropenias [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Most patients are diagnosed when a blood count is done during the evaluation of infection or as an incidental finding on a blood count done for other reasons. In one study of 240 infants, upper respiratory infection and otitis media accounted for 36 percent of infections at presentation; severe infections, such as pneumonia, meningitis, and sepsis occurred in 12 percent [<a href="#rid30">30</a>]. The propensity to infection correlates poorly with the severity of the neutropenia [<a href="#rid4">4,5,27</a>].</p><p>The absolute neutrophil count (ANC) is typically between 500 and 1000/microL and, in approximately one-fourth of patients, the monocyte count is above 1000/microL [<a href="#rid30">30</a>]. The bone marrow is typically normocellular or hypercellular, with a late maturational arrest at the band stage, consistent with a normal marrow reserve pool.</p><p class="headingAnchor" id="H7"><span class="h2">Diagnosis and differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of autoimmune neutropenia includes cyclic neutropenia and severe congenital neutropenia.</p><p class="bulletIndent1"><span class="glyph">●</span>Cyclic neutropenia classically occurs as neutropenic periods lasting three to six days and occurring approximately every 21 days. The patients often have symptoms every 21 days. This syndrome is very rare. (See  <a class="medical medical_review" href="/d/html/8370.html" rel="external">"Cyclic neutropenia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe congenital neutropenia is characterized by severe infections in the first month of life, the absence of spontaneous remission (as occurs in AIN), and maturational arrest of myelopoiesis at the promyelocyte stage. (See  <a class="medical medical_review" href="/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p></p><p>The diagnosis of autoimmune neutropenia can be assumed if the patient has isolated neutropenia, no dysmorphic features, no hepatosplenomegaly, no bone pain, no chronic diarrhea, no severe or unusual infections, and no other signs of other significant underlying disorders. The presence of an elevated sedimentation rate in the absence of clinical infection can indicate inflammation and may suggest a more serious type of neutropenia. Bone marrow aspiration is not critical unless there is evidence of deep tissue inflammation or chronic mucosal infection. Older children or adults should be screened for the presence of a collagen vascular disease. (See  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Other initial laboratory testing'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Treatment and clinical course</span><span class="headingEndMark"> — </span>Autoimmune neutropenia is typically characterized by spontaneous remission with disappearance of autoantibodies [<a href="#rid30">30,36</a>]. In one series of 34 infants who were followed for up to six years, neutropenia spontaneously disappeared in 30 after a median of 17 months (range 1 to 38 months); neutropenia lasted 7 to 24 months in 80 percent [<a href="#rid30">30</a>]. The mean time to recovery may be longer in those with a demonstrable autoantibody, and may be longest in those with the highest antibody "strength" [<a href="#rid37">37</a>].</p><p>Specific treatment of neutropenia is usually not required and observation with serial blood counts is the most common practice. Most patients remain free of infections and require no or minimal medical intervention. If the marrow cellularity is normal with sufficient late myeloid precursors, treatment of any kind simply to raise the ANC is not indicated. </p><p class="headingAnchor" id="H5127433"><span class="h3">Granulocyte colony-stimulating factor</span><span class="headingEndMark"> — </span>Granulocyte colony-stimulating factor (G-CSF) has dramatically improved the outcome for patients with more severe forms of congenital neutropenia, and has been effective in raising the neutrophil counts in small numbers of patients with autoimmune neutropenia [<a href="#rid30">30,38,39</a>]. In one report, for example, all eight patients treated with G-CSF (3 to 10 mcg/kg per day) attained an ANC above 1500/microL [<a href="#rid30">30</a>]. The increase in cell production induced by G-CSF in this setting presumably exceeds the effect of antibody binding.</p><p>Interpretation of the recommendations for use of G-CSF in the literature in neutropenia with normal marrow reserve is questionable, since these patients are able to deliver granulocytes to the tissues [<a href="#rid11">11</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Some authors have seen pyogenic granuloma in infants with CBN/AIN and report neutrophils in biopsies of the edge of the lesions yet recommended G-CSF [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a CBN/AIN infant with a fistula-in-ano that was draining purulent material, a clear sign of tissue delivery of granulocytes, was treated with G-CSF [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small subset of patients has CBN/AIN and are symptomatic with mucosal ulcerations that can be quite bothersome in spite of normal marrow findings. Two of the patients reported by Bernini [<a href="#rid42">42</a>] (the others had early myeloid arrest consistent with Kostmann syndrome) clinically improved with low dose G-CSF treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A very small number of patients with AIN/CBN [<a href="#rid30">30</a>] do have maturation arrests at the myelocyte or metamyelocyte stage and may benefit from G-CSF.</p><p></p><p>In general, neutrophil production and tissue delivery of granulocytes is normal in these patients and use of G-CSF is rarely, if ever, indicated [<a href="#rid4">4,5,43</a>]. Interestingly, when it is administered, the ANC corrects within approximately 12 hours, indicating release of neutrophils already present in the bone marrow into the circulation, rather than production of new neutrophils, which takes several days. (See  <a class="medical medical_review" href="/d/html/8380.html" rel="external">"Regulation of myelopoiesis"</a>.)</p><p class="headingAnchor" id="H5127440"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>High dose intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG, for a total of 1 to 3 grams/kg over two to five days) and/or corticosteroids (1 mg/kg per day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent) also have been effective in 50 to 60 percent of patients [<a href="#rid30">30,44,45</a>]. Potential side effects remain a concern with both of these drugs. Again, therapy to raise the ANC is not indicated if the marrow reserve is normal. (See  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p>If patients are clinically ill with recurrent infections or other symptoms related to their autoimmune disorder, it might be necessary to treat them aggressively. Again, we would caution against attributing infections to neutropenia if the marrow is normal. However, such complex immune cytopenias may warrant treatment with drugs such as <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>. The response to treatment with rituximab in patients with refractory autoimmune neutropenia has been generally disappointing, while anecdotal reports indicate a better response to treatment with alemtuzumab. (See <a class="local">'Pure white cell aplasia'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h1">CHRONIC IDIOPATHIC NEUTROPENIA</span><span class="headingEndMark"> — </span>The term chronic idiopathic neutropenia (CIN), also known as benign chronic neutropenia, is used to describe patients with chronic neutropenia for which there is no obvious cause. In contrast to the usual occurrence of autoimmune neutropenia in infancy, CIN tends to occur in late childhood or adulthood and does not undergo spontaneous remission [<a href="#rid46">46</a>].</p><p>CIN is essentially a diagnosis of exclusion. The absolute neutrophil count (ANC) is typically 500 to 1000/microL and is often accompanied by a monocytosis. Both the number and activity of natural killer cells may be reduced [<a href="#rid47">47</a>]. Bone marrow examination in CIN is nondiagnostic; cellularity is usually normal, although some patients show moderate hypocellularity, and approximately 25 percent demonstrate a myeloid maturation arrest [<a href="#rid48">48</a>]. Bone marrow cytogenetic studies and the serum G-CSF concentration are normal [<a href="#rid43">43,48</a>]. </p><p>In the original description of CIN, 14 of 15 patients were female and none experienced unexpected infectious complications with median follow-up of 15 years [<a href="#rid49">49,50</a>]. Subsequent studies from other referral centers reported another 70 patients and confirmed the female predominance, the absence of serious infections, the occasional presence of anemia, and the absence of splenomegaly [<a href="#rid48">48,51</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis of CIN is uncertain, but immunologic factors appear to be involved in at least some patients. In one of the early studies, antineutrophil antibodies were found in only 4 of 35 patients, one of whom had received multiple transfusions for autoimmune hemolytic anemia [<a href="#rid48">48</a>]. Later reports using more sensitive assays, however, have provided evidence to include at least some patients with this disorder in the immune neutropenias:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 121 adults with CIN, 36 percent had IgG and/or IgM antineutrophil antibodies [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, sera from 8 of 14 patients had inhibitory activity for myeloid colony formation in vitro (CFU-GM) [<a href="#rid53">53</a>]. The inhibitory activity correlated with myeloid hypoplasia and the presence of recurrent infections.</p><p></p><p>A possible explanation of the latter finding is that impaired granulocytopoiesis in CIN is due to overproduction of inflammatory cytokines (eg, Fas-ligand, interferon gamma) by activated T-lymphocytes within the bone marrow environment, leading to inhibition of myelopoiesis [<a href="#rid10">10,54,55</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Patients with CIN usually follow a benign course despite the degree of neutropenia. This may be because they have some marrow reserve, as demonstrated by an elevation in the ANC in response to a corticosteroid stimulation test [<a href="#rid48">48</a>]. These patients are also able to mobilize more neutrophils to tissues than can those with acute drug-induced suppression of equal degree [<a href="#rid11">11</a>], and most have a monocytosis that may be protective against infection.</p><p>For these reasons, treatment to increase the neutrophil count should be reserved for those patients with significant recurrent infectious complications. Corticosteroids, splenectomy, and cytotoxic agents have been of variable benefit in increasing neutrophil counts [<a href="#rid48">48</a>], while G-CSF has been used successfully to treat small numbers of adults and children [<a href="#rid42">42,56-59</a>]. In one study, for example, seven adults received a starting G-CSF dose of 3 mcg/kg per day and a maintenance dose that ranged from 0.1 to 8 mcg/kg per day [<a href="#rid59">59</a>]. All had a rapid increase in the ANC and maintenance therapy was associated with absence of severe infections at follow-up of up to 4.5 years. The discussion regarding use of G-CSF in AIN applies with CIN as well.</p><p class="headingAnchor" id="H12"><span class="h1">PURE WHITE CELL APLASIA</span><span class="headingEndMark"> — </span>Pure white cell aplasia (PWCA) is a rare disorder characterized by complete disappearance of granulocytopoietic tissue from the bone marrow, while erythropoiesis and megakaryocytopoiesis are normal [<a href="#rid60">60</a>]. The peripheral blood shows severe neutropenia (ANC &lt;500/microL).</p><p>Pure white cell aplasia is most often associated with thymoma, particularly the spindle cell type [<a href="#rid61">61-63</a>]; in other patients, thymoma has been associated with pure red cell aplasia (see  <a class="medical medical_review" href="/d/html/7120.html" rel="external">"Acquired pure red cell aplasia in adults"</a>). PWCA has also been reported as an idiosyncratic drug reaction due to <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> and chlorpropamide (no longer available in most settings), in association with antiglomerular basement membrane antibody disease (Goodpasture's syndrome) and as a primary idiopathic condition [<a href="#rid64">64-67</a>]. It occurs more frequently in women and presents with the typical clinical picture of agranulocytosis with severe, recurrent infections. Unlike other immune neutropenias, the myeloid reserve is very low or absent. These patients are at significant risk of bacterial infections because of the neutropenia.</p><p class="headingAnchor" id="H13"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Immunologic mechanisms can be demonstrated in virtually all patients with PWCA [<a href="#rid60">60</a>]. In vitro studies indicate lymphocyte or serum-mediated inhibition of normal marrow growth. Most cases appear to be due to the presence of antibodies, and GM-CFU inhibitory activity has been demonstrated in the sera of all patients with thymoma-associated disease [<a href="#rid60">60-63</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>In some cases, PWCA resolves following thymectomy. In others, the addition of immunosuppressive therapy is necessary. Corticosteroids, high dose <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>, <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> have been reported as effective in the management of the neutropenia [<a href="#rid60">60,68</a>]. Transient remission has also been achieved in several patients with plasmapheresis [<a href="#rid61">61</a>] but, in other cases, it has been ineffective [<a href="#rid64">64</a>]. One patient with promyelocytic arrest and hypogammaglobulinemia, who did not respond to thymectomy, was treated successfully with G-CSF [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H16"><span class="h1">NEUTROPENIA ASSOCIATED WITH IMMUNE DEFICIENCIES</span><span class="headingEndMark"> — </span>Neutropenia can occur in association with a number of immune deficiency disorders. These include hypergammaglobulinemia or hypogammaglobulinemia [<a href="#rid67">67,70-72</a>], T cell defects [<a href="#rid73">73,74</a>], and natural killer (NK) cell dysfunction [<a href="#rid75">75</a>]. Many of these patients have a positive family history of neutropenia [<a href="#rid67">67,70,71</a>]. Particularly in patients with symptoms of neutropenia (eg, gingivitis, recurring fever, mucosal infections, rheumatological issues), it is important to look for underlying immunodeficiency disorders and inflammasomopathies [<a href="#rid10">10</a>].</p><p>Affected patients usually present in childhood with frequent bacterial infections, hepatosplenomegaly, and failure to thrive. Chronic diarrhea, rash, and recurrent viral infections may also be seen. Some of the children die within the first few years of life.</p><p>It is important to distinguish these patients from those with the much more common syndromes of chronic idiopathic or chronic benign neutropenia of infants and children. In contrast to these disorders, children with global immune defects associated with neutropenia have manifestations of recurrent or unusual infections. Thus, children who fail to thrive and have pneumonia or sepsis associated with their neutropenia should undergo an immunologic evaluation. Furthermore, live-virus vaccines must be withheld and any blood product irradiated prior to administration until the possibility of a T cell defect has been eliminated. (See  <a class="medical medical_review" href="/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a> and  <a class="medical medical_review" href="/d/html/8388.html" rel="external">"Laboratory evaluation of neutrophil disorders"</a>.)</p><p>Treatment of these disorders depends on the constellation of immunologic abnormalities present. Some patients have been treated with hematopoietic cell transplantation [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H22082928"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Neutropenia is defined as an absolute neutrophil count (ANC) &lt;1500/microL. ANC is calculated (<a class="calc calc_professional" href="/d/html/13483.html" rel="external">calculator 1</a>) as follows: </p><p></p><p class="bulletIndent1">ANC = WBC (cells/microL) x percent (PMNs + bands) ÷ 100</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of neutropenia</strong> – The evaluation of neutropenia in adults and children is discussed separately. (See  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia"</a> and  <a class="medical medical_review" href="/d/html/8375.html" rel="external">"Overview of neutropenia in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1">Some individuals have isolated mild neutropenia (usually &gt;1000/microL) in association with the Duffy null [Fy(a-b-)] red blood cell phenotype. This condition is more common in individuals of African descent and in Sephardic Jews, West Indians, Yemenites, Greeks, and Arabs; it was formerly called constitutional neutropenia or benign ethnic neutropenia and is described separately. (See  <a class="medical medical_review" href="/d/html/90654.html" rel="external">"Approach to the adult with unexplained neutropenia", section on 'Normal variants &lt;1500/microL'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Significance of immune neutropenia </strong>– Immune destruction of neutrophils accounts for many cases of isolated neutropenia. Most affected individuals have normal marrow reserves and little, if any, increased propensity to infection, regardless of the degree of neutropenia. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders associated with immune neutropenia</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonatal alloimmune neutropenia</strong> – Moderate to severe neutropenia can occur in newborn infants due to the transplacental passage of IgG antibodies to neutrophil-specific antigens inherited from the father or mother. (See <a class="local">'Neonatal isoimmune (alloimmune) neutropenia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autoimmune neutropenia </strong>– Autoimmune neutropenia (AIN) is caused by granulocyte-specific antibodies and has been associated with a variety of underlying diseases. (See <a class="local">'Autoimmune neutropenia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic idiopathic neutropenia </strong>– Chronic idiopathic neutropenia (CIN; benign chronic neutropenia) describes patients for which there is no obvious cause. (See <a class="local">'Chronic idiopathic neutropenia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pure white cell aplasia </strong>– Pure white cell aplasia (PWCA) is a rare antibody-mediated disorder characterized by complete disappearance of granulocytopoietic tissue from the bone marrow and is most often associated with thymoma. (See <a class="local">'Pure white cell aplasia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neutropenia associated with immune deficiency </strong>– Neutropenia can occur in association with immune deficiency disorders. Such children have manifestations of recurrent or unusual infections. (See <a class="local">'Neutropenia associated with immune deficiencies'</a> above.)</p><p></p><p class="headingAnchor" id="H3504765405"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges the late Laurence A Boxer, MD, for his previous role as a section editor for this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liles WC, Starkebaum G, Dale DC. Neutropenia in systemic lupus erythematosus. Blood 2004; 104:2.</a></li><li><a class="nounderline abstract_t">Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin Hematol 2002; 39:121.</a></li><li><a class="nounderline abstract_t">Kyono W, Coates TD. A practical approach to neutrophil disorders. Pediatr Clin North Am 2002; 49:929.</a></li><li><a class="nounderline abstract_t">Koene HR, de Haas M, Kleijer M, et al. Clinical value of soluble IgG Fc receptor type III in plasma from patients with chronic idiopathic neutropenia. Blood 1998; 91:3962.</a></li><li><a class="nounderline abstract_t">Muller Kobold AC, Zijlstra JG, Koene HR, et al. Levels of soluble Fc gammaRIII correlate with disease severity in sepsis. Clin Exp Immunol 1998; 114:220.</a></li><li><a class="nounderline abstract_t">Sella R, Flomenblit L, Goldstein I, Kaplinsky C. Detection of anti-neutrophil antibodies in autoimmune neutropenia of infancy: a multicenter study. Isr Med Assoc J 2010; 12:91.</a></li><li><a class="nounderline abstract_t">Farruggia P. Immune neutropenias of infancy and childhood. World J Pediatr 2016; 12:142.</a></li><li><a class="nounderline abstract_t">Farruggia P, Fioredda F, Puccio G, et al. Autoimmune neutropenia of infancy: Data from the Italian neutropenia registry. Am J Hematol 2015; 90:E221.</a></li><li><a class="nounderline abstract_t">Clay ME, Schuller RM, Bachowski GJ. Granulocyte serology: current concepts and clinical signifcance. Immunohematology 2010; 26:11.</a></li><li><a class="nounderline abstract_t">Fioredda F, Dufour C, Höglund P, et al. Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults. Hemasphere 2023; 7:e814.</a></li><li><a class="nounderline abstract_t">Wright DG, Meierovics AI, Foxley JM. Assessing the delivery of neutrophils to tissues in neutropenia. Blood 1986; 67:1023.</a></li><li><a class="nounderline abstract_t">Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764.</a></li><li class="breakAll">Lalezari P, Khorshidi M. Neutrophil and platelet antibodies in immune neutropenia and thrombocytopenia. In: Manual of Clinical Laboratory Immunology, 4th ed, Rose NR, Conway De Macario E, Fahey JL, et al. (Eds), American Society of Microbiology, Washington, DC.</li><li><a class="nounderline abstract_t">Karakilic-Ozturan E, Karaman S, Soguksu P, et al. The Role of Anti-Neutrophil Antibodies in the Etiologic Classification of Childhood Neutropenia: A Cross-Sectional Study in a Tertiary Center. J Pediatr Hematol Oncol 2020; 42:107.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl 2002; 91:98.</a></li><li><a class="nounderline abstract_t">Black LV, Maheshwari A. Immune-mediated neutropenia in the neonate. Neoreviews 2009; 10:e446.</a></li><li><a class="nounderline abstract_t">Kameoka J, Funato T, Miura T, et al. Autoimmune neutropenia in pregnant women causing neonatal neutropenia. Br J Haematol 2001; 114:198.</a></li><li><a class="nounderline abstract_t">Davoren A, Saving K, McFarland JG, et al. Neonatal neutropenia and bacterial sepsis associated with placental transfer of maternal neutrophil-specific autoantibodies. Transfusion 2004; 44:1041.</a></li><li><a class="nounderline abstract_t">Christensen RD, Bradley PP, Rothstein G. The leukocyte left shift in clinical and experimental neonatal sepsis. J Pediatr 1981; 98:101.</a></li><li><a class="nounderline abstract_t">Manroe BL, Rosenfeld CR, Weinberg AG, Browne R. The differential leukocyte count in the assessment and outcome of early-onset neonatal group B streptococcal disease. J Pediatr 1977; 91:632.</a></li><li><a class="nounderline abstract_t">Manroe B, Browne R, Weinberg A, et al. Leukocyte count in streptococcal disease. Pediatr Res 1976; 10:428.</a></li><li><a class="nounderline abstract_t">Christensen RD, Rothstein G. Exhaustion of mature marrow neutrophils in neonates with sepsis. J Pediatr 1980; 96:316.</a></li><li><a class="nounderline abstract_t">Rodwell RL, Gray PH, Taylor KM, Minchinton R. Granulocyte colony stimulating factor treatment for alloimmune neonatal neutropenia. Arch Dis Child Fetal Neonatal Ed 1996; 75:F57.</a></li><li><a class="nounderline abstract_t">Curtis BR, Reno C, Aster RH. Neonatal alloimmune neutropenia attributed to maternal immunoglobulin G antibodies against the neutrophil alloantigen HNA-1c (SH): a report of five cases. Transfusion 2005; 45:1308.</a></li><li><a class="nounderline abstract_t">Schibler KR, Osborne KA, Leung LY, et al. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics 1998; 102:6.</a></li><li><a class="nounderline abstract_t">Soza A, Lau DT, Khokhar MF, et al. Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy. J Pediatr Gastroenterol Nutr 2003; 36:141.</a></li><li><a class="nounderline abstract_t">Logue GL, Shimm DS. Autoimmune granulocytopenia. Annu Rev Med 1980; 31:191.</a></li><li><a class="nounderline abstract_t">Lima CS, Paula EV, Takahashi T, et al. Causes of incidental neutropenia in adulthood. Ann Hematol 2006; 85:705.</a></li><li><a class="nounderline abstract_t">Nakamura K, Miki M, Mizoguchi Y, et al. Deficiency of regulatory T cells in children with autoimmune neutropenia. Br J Haematol 2009; 145:642.</a></li><li><a class="nounderline abstract_t">Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998; 91:181.</a></li><li><a class="nounderline abstract_t">Lalezari P, Khorshidi M, Petrosova M. Autoimmune neutropenia of infancy. J Pediatr 1986; 109:764.</a></li><li><a class="nounderline abstract_t">Bux J, Kissel K, Nowak K, et al. Autoimmune neutropenia: clinical and laboratory studies in 143 patients. Ann Hematol 1991; 63:249.</a></li><li><a class="nounderline abstract_t">Bux J, Mueller-Eckhardt G, Mueller-Eckhardt C. Autoimmunization against the neutrophil-specific NA1 antigen is associated with HLA-DR2. Hum Immunol 1991; 30:18.</a></li><li><a class="nounderline abstract_t">Wang LY, Wang CL, Chu CC, et al. Primary autoimmune neutropenia in children in Taiwan. Transfusion 2009; 49:1003.</a></li><li><a class="nounderline abstract_t">Nadeau KC, Callejas A, Wong WB, et al. Idiopathic neutropenia of childhood is associated with Fas/FasL expression. Clin Immunol 2008; 129:438.</a></li><li><a class="nounderline abstract_t">Conway LT, Clay ME, Kline WE, et al. Natural history of primary autoimmune neutropenia in infancy. Pediatrics 1987; 79:728.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Nakamura K, Kawaguchi H, et al. Significance of the detection of antineutrophil antibodies in children with chronic neutropenia. Blood 2002; 99:3468.</a></li><li><a class="nounderline abstract_t">Kuijpers TW, de Haas M, de Groot CJ, et al. The use of rhG-CSF in chronic autoimmune neutropenia: reversal of autoimmune phenomena, a case history. Br J Haematol 1996; 94:464.</a></li><li><a class="nounderline abstract_t">Krishnan K, Ross CW, Bockenstedt PL, Adams PT. Successful treatment of autoimmune neutropenia with recombinant human granulocyte-colony stimulating factor (R-metHuG-CSF). Clin Lab Haematol 1997; 19:105.</a></li><li><a class="nounderline abstract_t">Mehta AJ, Charman CR. Pyoderma gangrenosum in association with autoimmune neutropenia of infancy. Pediatr Dermatol 2008; 25:620.</a></li><li><a class="nounderline abstract_t">Lejkowski M, Maheshwari A, Calhoun DA, et al. Persistent perianal abscess in early infancy as a presentation of autoimmune neutropenia. J Perinatol 2003; 23:428.</a></li><li><a class="nounderline abstract_t">Bernini JC, Wooley R, Buchanan GR. Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia. J Pediatr 1996; 129:551.</a></li><li><a class="nounderline abstract_t">Kawaguchi Y, Kobayashi M, Tanabe A, et al. Granulopoiesis in patients with congenital neutropenia. Am J Hematol 1985; 20:223.</a></li><li><a class="nounderline abstract_t">Bussel J, Lalezari P, Hilgartner M, et al. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood 1983; 62:398.</a></li><li><a class="nounderline abstract_t">Hilgartner MW, Bussel J. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 1987; 83:25.</a></li><li><a class="nounderline abstract_t">Sicre de Fontbrune F, Moignet A, Beaupain B, et al. Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood 2015; 126:1643.</a></li><li><a class="nounderline abstract_t">Papadaki HA, Coulocheri S, Xylouri I, et al. Defective natural killer cell activity of peripheral blood lymphocytes correlates with the degree of neutropenia in patients with chronic idiopathic neutropenia of adults. Ann Hematol 1998; 76:127.</a></li><li><a class="nounderline abstract_t">Dale DC, Guerry D 4th, Wewerka JR, et al. Chronic neutropenia. Medicine (Baltimore) 1979; 58:128.</a></li><li><a class="nounderline abstract_t">Kyle RA, Linman JW. Chronic idiopathic neutropenia. A newly recognized entity? N Engl J Med 1968; 279:1015.</a></li><li><a class="nounderline abstract_t">Kyle RA. Natural history of chronic idiopathic neutropenia. N Engl J Med 1980; 302:908.</a></li><li><a class="nounderline abstract_t">Greenberg PL, Mara B, Steed S, Boxer L. The chronic idiopathic neutropenia syndrome: correlation of clinical features with in vitro parameters of granulocytopoiesis. Blood 1980; 55:915.</a></li><li><a class="nounderline abstract_t">Logue GL, Shastri KA, Laughlin M, et al. Idiopathic neutropenia: antineutrophil antibodies and clinical correlations. Am J Med 1991; 90:211.</a></li><li><a class="nounderline abstract_t">van der Veen JP, Hack CE, Engelfriet CP, et al. Chronic idiopathic and secondary neutropenia: clinical and serological investigations. Br J Haematol 1986; 63:161.</a></li><li><a class="nounderline abstract_t">Papadaki HA, Eliopoulos AG, Kosteas T, et al. Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood 2003; 101:2591.</a></li><li><a class="nounderline abstract_t">Papadaki HA, Stamatopoulos K, Damianaki A, et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. Br J Haematol 2005; 128:863.</a></li><li><a class="nounderline abstract_t">Jakubowski AA, Souza L, Kelly F, et al. Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 1989; 320:38.</a></li><li><a class="nounderline abstract_t">Furukawa T, Takahashi M, Moriyama Y, et al. Successful treatment of chronic idiopathic neutropenia using recombinant granulocyte colony-stimulating factor. Ann Hematol 1991; 62:22.</a></li><li><a class="nounderline abstract_t">Morikawa K, Oiwa K, Oseko F, et al. Distinct effect of G-CSF on the growth and differentiation of myeloid progenitor cells from chronic idiopathic neutropenia. Intern Med 1995; 34:384.</a></li><li><a class="nounderline abstract_t">Heussner P, Haase D, Kanz L, et al. G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients. Int J Hematol 1995; 62:225.</a></li><li><a class="nounderline abstract_t">Marinone G, Roncoli B, Marinone MG Jr. Pure white cell aplasia. Semin Hematol 1991; 28:298.</a></li><li><a class="nounderline abstract_t">Degos L, Faille A, Housset M, et al. Syndrome of neutrophil agranulocytosis, hypogammaglobulinemia, and thymoma. Blood 1982; 60:968.</a></li><li><a class="nounderline abstract_t">Ackland SP, Bur ME, Adler SS, et al. White blood cell aplasia associated with thymoma. Am J Clin Pathol 1988; 89:260.</a></li><li><a class="nounderline abstract_t">Mathieson PW, O'Neill JH, Durrant ST, et al. Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma: case report and literature review. Q J Med 1990; 74:57.</a></li><li><a class="nounderline abstract_t">Levitt LJ. Chlorpropamide-induced pure white cell aplasia. Blood 1987; 69:394.</a></li><li><a class="nounderline abstract_t">Mamus SW, Burton JD, Groat JD, et al. Ibuprofen-associated pure white-cell aplasia. N Engl J Med 1986; 314:624.</a></li><li><a class="nounderline abstract_t">Firkin FC, Prewett EJ, Nicholls K, Moran J. Antithymocyte globulin therapy for pure white cell aplasia. Am J Hematol 1987; 25:101.</a></li><li><a class="nounderline abstract_t">Lonsdale D, Deodhar SD, Mercer RD. Familial granulocytopenia and associated immunoglobulin abnormality. Report of three cases in young brothers. J Pediatr 1967; 71:790.</a></li><li><a class="nounderline abstract_t">Risitano AM, Selleri C, Serio B, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148:791.</a></li><li><a class="nounderline abstract_t">Yip D, Rasko JE, Lee C, et al. Thymoma and agranulocytosis: two case reports and literature review. Br J Haematol 1996; 95:52.</a></li><li><a class="nounderline abstract_t">Webster AD, Slavin G, Strelling MK, Asherson GL. Combined immunodeficiency with hyper-gamma-globulinaemia. Arch Dis Child 1975; 50:486.</a></li><li><a class="nounderline abstract_t">Björkstén B, Lundmark KM. Recurrent bacterial infections in four siblings with neutropenia, eosinophilia, hyperimmunoglobulinemia A, and defective neutrophil chemotaxis. J Infect Dis 1976; 133:63.</a></li><li><a class="nounderline abstract_t">Al Ghaithi I, Wright NA, Breakey VR, et al. Combined Autoimmune Cytopenias Presenting in Childhood. Pediatr Blood Cancer 2016; 63:292.</a></li><li><a class="nounderline abstract_t">Perreault C, Bonny Y, Gyger M, et al. Congenital T cell deficiency with neutropenia and erythroblastopenia. Correction following allogeneic bone marrow transplantation. Transplantation 1985; 39:321.</a></li><li><a class="nounderline abstract_t">Herrod HG, Wang WC, Sullivan JL. Chronic T-cell lymphocytosis with neutropenia. Its association with Epstein-Barr virus infection. Am J Dis Child 1985; 139:405.</a></li><li><a class="nounderline abstract_t">Currie MS, Weinberg JB, Rustagi PK, Logue GL. Antibodies to granulocyte precursors in selective myeloid hypoplasia and other suspected autoimmune neutropenias: use of HL-60 cells as targets. Blood 1987; 69:529.</a></li></ol></div><div id="topicVersionRevision">Topic 8371 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neutropenia in systemic lupus erythematosus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11957195" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chronic neutropenia associated with autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12430620" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A practical approach to neutrophil disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573035" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical value of soluble IgG Fc receptor type III in plasma from patients with chronic idiopathic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822280" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Levels of soluble Fc gammaRIII correlate with disease severity in sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20550032" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Detection of anti-neutrophil antibodies in autoimmune neutropenia of infancy: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26582295" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immune neutropenias of infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361081" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Autoimmune neutropenia of infancy: Data from the Italian neutropenia registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20795313" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Granulocyte serology: current concepts and clinical signifcance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36570693" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3955227" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Assessing the delivery of neutrophils to tissues in neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190991" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : How I treat LGL leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190991" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : How I treat LGL leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31895216" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Role of Anti-Neutrophil Antibodies in the Etiologic Classification of Childhood Neutropenia: A Cross-Sectional Study in a Tertiary Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12477271" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Immune-mediated neutropenia in the neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Immune-mediated neutropenia in the neonate</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472368" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Autoimmune neutropenia in pregnant women causing neonatal neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15225245" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neonatal neutropenia and bacterial sepsis associated with placental transfer of maternal neutrophil-specific autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7192731" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The leukocyte left shift in clinical and experimental neonatal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/333072" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The differential leukocyte count in the assessment and outcome of early-onset neonatal group B streptococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Leukocyte count in streptococcal disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6985958" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Exhaustion of mature marrow neutrophils in neonates with sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795359" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Granulocyte colony stimulating factor treatment for alloimmune neonatal neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16078917" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neonatal alloimmune neutropenia attributed to maternal immunoglobulin G antibodies against the neutrophil alloantigen HNA-1c (SH): a report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9651406" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12500011" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6994605" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Autoimmune granulocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807747" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Causes of incidental neutropenia in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19344427" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Deficiency of regulatory T cells in children with autoimmune neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9414283" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3534197" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Autoimmune neutropenia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1958748" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Autoimmune neutropenia: clinical and laboratory studies in 143 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2001973" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Autoimmunization against the neutrophil-specific NA1 antigen is associated with HLA-DR2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19210322" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary autoimmune neutropenia in children in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18819843" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Idiopathic neutropenia of childhood is associated with Fas/FasL expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3155359" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Natural history of primary autoimmune neutropenia in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964321" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Significance of the detection of antineutrophil antibodies in children with chronic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790143" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The use of rhG-CSF in chronic autoimmune neutropenia: reversal of autoimmune phenomena, a case history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9218149" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Successful treatment of autoimmune neutropenia with recombinant human granulocyte-colony stimulating factor (R-metHuG-CSF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19067867" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pyoderma gangrenosum in association with autoimmune neutropenia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847542" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Persistent perianal abscess in early infancy as a presentation of autoimmune neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8859262" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low-dose recombinant human granulocyte colony-stimulating factor therapy in children with symptomatic chronic idiopathic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3877459" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Granulopoiesis in patients with congenital neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6191800" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3118705" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261239" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Severe chronic primary neutropenia in adults: report on a series of 108 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9619729" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Defective natural killer cell activity of peripheral blood lymphocytes correlates with the degree of neutropenia in patients with chronic idiopathic neutropenia of adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/431399" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chronic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4878668" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic idiopathic neutropenia. A newly recognized entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7360177" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Natural history of chronic idiopathic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7378580" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The chronic idiopathic neutropenia syndrome: correlation of clinical features with in vitro parameters of granulocytopoiesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1996590" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Idiopathic neutropenia: antineutrophil antibodies and clinical correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3518783" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic idiopathic and secondary neutropenia: clinical and serological investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517813" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15755293" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2462670" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1709572" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Successful treatment of chronic idiopathic neutropenia using recombinant granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7544173" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Distinct effect of G-CSF on the growth and differentiation of myeloid progenitor cells from chronic idiopathic neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589368" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : G-CSF in the long-term treatment of cyclic neutropenia and chronic idiopathic neutropenia in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1759170" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pure white cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7115963" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Syndrome of neutrophil agranulocytosis, hypogammaglobulinemia, and thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341286" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : White blood cell aplasia associated with thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2326435" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3801659" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Chlorpropamide-induced pure white cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3945248" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ibuprofen-associated pure white-cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3495175" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antithymocyte globulin therapy for pure white cell aplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4168442" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Familial granulocytopenia and associated immunoglobulin abnormality. Report of three cases in young brothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995389" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857938" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Thymoma and agranulocytosis: two case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1147691" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Combined immunodeficiency with hyper-gamma-globulinaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1245758" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Recurrent bacterial infections in four siblings with neutropenia, eosinophilia, hyperimmunoglobulinemia A, and defective neutrophil chemotaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26397379" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Combined Autoimmune Cytopenias Presenting in Childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883599" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Congenital T cell deficiency with neutropenia and erythroblastopenia. Correction following allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2983532" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Chronic T-cell lymphocytosis with neutropenia. Its association with Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3801668" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Antibodies to granulocyte precursors in selective myeloid hypoplasia and other suspected autoimmune neutropenias: use of HL-60 cells as targets.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
